X0306 4 2022-06-01 0001682852 Moderna, Inc. MRNA 0001443340 Bancel Stephane C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 1 Chief Executive Officer Common Stock 2022-06-01 4 M 0 40000 .99 A 5451946 D Common Stock 2022-06-01 4 S 0 3166 141.67 D 5448780 D Common Stock 2022-06-01 4 S 0 13056 142.51 D 5435724 D Common Stock 2022-06-01 4 S 0 12049 143.58 D 5423675 D Common Stock 2022-06-01 4 S 0 5329 144.33 D 5418346 D Common Stock 2022-06-01 4 S 0 4137 145.62 D 5414209 D Common Stock 2022-06-01 4 S 0 1063 146.65 D 5413146 D Common Stock 2022-06-01 4 S 0 800 147.46 D 5412346 D Common Stock 2022-06-01 4 S 0 400 148.44 D 5411946 D Common Stock 2022-06-02 4 M 0 40000 .99 A 5451946 D Common Stock 2022-06-02 4 S 0 1200 131.56 D 5450746 D Common Stock 2022-06-02 4 S 0 900 132.68 D 5449846 D Common Stock 2022-06-02 4 S 0 10100 134.06 D 5439746 D Common Stock 2022-06-02 4 S 0 7000 135.12 D 5432746 D Common Stock 2022-06-02 4 S 0 300 136.72 D 5432446 D Common Stock 2022-06-02 4 S 0 14000 138.58 D 5418446 D Common Stock 2022-06-02 4 S 0 6500 139.79 D 5411946 D Common Stock 2022-06-02 4 S 0 10000 140.00 D 6864880 I See Footnote Common Stock 9050372 I See Footnote Stock Option (Right to Buy) .99 2022-06-01 4 M 0 40000 0 D 2023-08-19 Common Stock 40000 4467155 D Stock Option (Right to Buy) .99 2022-06-02 4 M 0 40000 0 D 2023-08-19 Common Stock 40000 4427155 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.97 to $141.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.98 to $142.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.99 to $143.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.00 to $144.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.01 to $146.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.06 to $147.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.09 to $147.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.20 to $148.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.16 to $131.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.17 to $133.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.20 to $134.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.28 to $135.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.53 to $136.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.10 to $139.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.21 to $140.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. This option is fully vested and exercisable. /s/ Brian Sandstrom, as Attorney-in-Fact 2022-06-03